Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Methylestradiol

From Wikipedia, the free encyclopedia
Chemical compound
Not to be confused with7α-Methylestradiol.
Pharmaceutical compound
Methylestradiol
Clinical data
Trade namesGinecosid, Ginecoside, Mediol, Renodiol
Other namesNSC-52245; 17α-Methylestradiol; 17α-ME; 17α-Methylestra-1,3,5(10)-triene-3,17β-diol
Routes of
administration
By mouth[1]
Drug classEstrogen
Identifiers
  • (8R,9S,13S,14S,17S)-13,17-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.005.572Edit this at Wikidata
Chemical and physical data
FormulaC19H26O2
Molar mass286.415 g·mol−1
3D model (JSmol)
  • CC12CCC3C(C1CCC2(C)O)CCC4=C3C=CC(=C4)O
  • InChI=1S/C19H26O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h4,6,11,15-17,20-21H,3,5,7-10H2,1-2H3/t15-,16-,17+,18+,19+/m1/s1
  • Key:JXQJDYXWHSVOEF-GFEQUFNTSA-N

Methylestradiol, sold under the brand namesGinecosid,Ginecoside,Mediol, andRenodiol, is anestrogen medication which is used in the treatment ofmenopausal symptoms.[2][3][4] It is formulated in combination withnormethandrone, aprogestin andandrogen/anabolic steroid medication.[3][4] Methylestradiol is takenby mouth.[1]

Side effects of methylestradiol includenausea,breast tension,edema, andbreakthrough bleeding among others.[5] It is anestrogen, or anagonist of theestrogen receptors, thebiological target of estrogens likeestradiol.[6]

Methylestradiol is or has been marketed inBrazil,Venezuela, andIndonesia.[3] In addition to its use as a medication, methylestradiol has been studied for use as aradiopharmaceutical for theestrogen receptor.[7]

Medical uses

[edit]

Methylestradiol is used in combination with the progestin and androgen/anabolic steroidnormethandrone (methylestrenolone) in the treatment ofmenopausal symptoms.[3][4]

Available forms

[edit]

Methylestradiol is marketed in combination withnormethandrone in the form oforaltablets containing 0.3 mg methylestradiol and 5 mg normethandrone.[8][9]

Side effects

[edit]

Side effects of methylestradiol includenausea,breast tension,edema, andbreakthrough bleeding.[5]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Methylestradiol is anestrogen, or anagonist of theestrogen receptor.[6] It shows somewhat loweraffinity for the estrogen receptor thanestradiol orethinylestradiol.[6]

Methylestradiol is anactive metabolite of the androgens/anabolic steroidsmethyltestosterone (17α-methyltestosterone),metandienone (17α-methyl-δ1-testosterone), andnormethandrone (17α-methyl-19-nortestosterone), and is responsible for theirestrogenicside effects, such asgynecomastia andfluid retention.[10][11][12]

Relative affinities (%) of methylestradiol and related steroids
CompoundPRTooltip Progesterone receptorARTooltip Androgen receptorERTooltip Estrogen receptorGRTooltip Glucocorticoid receptorMRTooltip Mineralocorticoid receptorSHBGTooltip Sex hormone-binding globulinCBGTooltip Corticosteroid binding globulin
Estradiol2.67.91000.60.138.7<0.1
Ethinylestradiol15–251–31121–3<1??
Methylestradiol3–10, 15–251–3671–3<1??
Methyltestosterone345, 100–125?1–5?5?
Normethandrone100146<0.11.50.6??
Sources: Values are percentages (%). Referenceligands (100%) wereprogesterone for thePRTooltip progesterone receptor,testosterone for theARTooltip androgen receptor,E2 for theERTooltip estrogen receptor,DEXATooltip dexamethasone for theGRTooltip glucocorticoid receptor,aldosterone for theMRTooltip mineralocorticoid receptor,DHTTooltip dihydrotestosterone forSHBGTooltip sex hormone-binding globulin, andcortisol forCBGTooltip Corticosteroid-binding globulin.Sources:[13][6][14][15]

Pharmacokinetics

[edit]

Due to the presence of its C17αmethyl group, methylestradiol cannot be deactivated byoxidation of the C17βhydroxyl group, resulting in improvedmetabolic stability andpotency relative toestradiol.[10] This is analogous to the case ofethinylestradiol and its C17αethynyl group.[10]

Chemistry

[edit]
See also:List of estrogens

Methylestradiol, or 17α-methylestradiol (17α-ME), also known as 17α-methylestra-1,3,5(10)-triene-3,17β-diol, is asyntheticestranesteroid and aderivative ofestradiol.[2][3] It is specifically the derivative of estradiol with amethyl group at the C17α positions.[2][3] Closely related steroids includeethinylestradiol (17α-ethynylestradiol) andethylestradiol (17α-ethylestradiol).[2] The C3cyclopentylether of methylestradiol has been studied and shows greateroralpotency than methylestradiol in animals, similarly toquinestrol (ethinylestradiol 3-cyclopentyl ether) andquinestradol (estriol 3-cyclopentyl ether).[16]

Synthesis

[edit]

The procedure involving organometallic addition ofmethyl lithium toestrone works in very high yield but not theGrignard reagent.[17][18] The patent stated that methylestradiol has the advantage that it is orally much more active than estradiol.

History

[edit]

Methylestradiol was first marketed, alone as Follikosid and in combination withmethyltestosterone as Klimanosid, in 1955.[19][20][21][22]

Society and culture

[edit]

Generic names

[edit]

Methylestradiol has not been assigned anINNTooltip International Nonproprietary Name or other formal name designations.[2][3] Itsgeneric name inEnglish andGerman ismethylestradiol, inFrench isméthylestradiol, and inSpanish ismetilestadiol.[3] It is also known as17α-methylestradiol.[3]

Brand names

[edit]

Methylestradiol is or has been marketed under the brand names Ginecosid, Ginecoside, Mediol, and Renodiol, all in combination withnormethandrone.[3][2]

Availability

[edit]

Methylestradiol is or has been marketed inBrazil,Venezuela, andIndonesia.[3]

References

[edit]
  1. ^abHegemann O (May 1959). "[Oral hormonal treatment with methylestrene-olone & methylestradiol as early pregnancy tests]".Die Medizinische (in German).4 (21):1032–1033.PMID 13673847.
  2. ^abcdefElks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 898–.ISBN 978-1-4757-2085-3.
  3. ^abcdefghijk"Methylestradiol".Drugs.com. Retrieved2 January 2016.
  4. ^abcIARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007).Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 389–.ISBN 978-92-832-1291-1.
  5. ^abWittlinger H (1980). "Clinical Effects of Estrogens".Functional Morphologic Changes in Female Sex Organs Induced by Exogenous Hormones. pp. 67–71.doi:10.1007/978-3-642-67568-3_10.ISBN 978-3-642-67570-6.
  6. ^abcdOjasoo T, Raynaud JP (November 1978)."Unique steroid congeners for receptor studies".Cancer Research.38 (11 Pt 2):4186–4198.PMID 359134.
  7. ^Feenstra A, Vaalburg W, Nolten GM, Reiffers S, Talma AG, Wiegman T, et al. (June 1983). "Estrogen receptor binding radiopharmaceuticals: II. Tissue distribution of 17 alpha-methylestradiol in normal and tumor-bearing rats".Journal of Nuclear Medicine.24 (6):522–528.PMID 6406650.
  8. ^Unlisted Drugs. Pharmaceutical Section, Special Libraries Association. 1982.Batynid. C. Each dragee contains: normethandrone, 5 mg.; and methylestradiol, 0.3 mg. E. (Formerly) Gynaekosid. M. Boehringer Biochemia, Florence. A. Estrogenic; Rx of secondary amenorrhea. R. Notiz Med Farm 32;295, Nov-Dec 81.
  9. ^Akingba JB, Ayodeji EA (February 1966). "Amenorrhea as a leading symptom of choriocarcinoma".The Journal of Obstetrics and Gynaecology of the British Commonwealth.73 (1):153–155.doi:10.1111/j.1471-0528.1966.tb05137.x.PMID 5948541.S2CID 38008851.
  10. ^abcThieme D, Hemmersbach P (18 December 2009).Doping in Sports. Springer Science & Business Media. pp. 470–.ISBN 978-3-540-79088-4.
  11. ^Llewellyn W (2011).Anabolics. Molecular Nutrition Llc. pp. 533–.ISBN 978-0-9828280-1-4.
  12. ^Friedl KE (1990). "Reappraisal of the health risks associated with the use of high doses of oral and injectable androgenic steroids".NIDA Research Monograph.102:142–177.PMID 1964199.
  13. ^Raynaud JP, Ojasoo T, Bouton MM, Philibert D (1979)."Receptor Binding as a Tool in the Development of New Bioactive Steroids".Drug Design. pp. 169–214.doi:10.1016/B978-0-12-060308-4.50010-X.ISBN 9780120603084.
  14. ^Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors".Journal of Steroid Biochemistry.27 (1–3):255–269.doi:10.1016/0022-4731(87)90317-7.PMID 3695484.
  15. ^Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, et al. (January 1980). "Steroid hormone receptors and pharmacology".Journal of Steroid Biochemistry.12:143–157.doi:10.1016/0022-4731(80)90264-2.PMID 7421203.
  16. ^Falconi G, Rossi GL, Ercoli A (September 1970). James VH (ed.).Quinestrol and other cyclopentyl ethers of estrogenic steroids: different rates of storage in body fat. Third International Congress on Hormonal Steroids, Hamburg. International Congress Series No. 210. Amsterdam, Excerpta Medica. pp. 218–219. Archived fromthe original on 28 March 2018.
  17. ^Stoeck Georg & Voigt Hans,U.S. patent 2,857,405 (1958 to Roche Diagnostics GmbH).
  18. ^Boivin, R. P., Luu-The, V., Lachance, R., Labrie, F., Poirier, D. (1 November 2000)."Structure−Activity Relationships of 17α-Derivatives of Estradiol as Inhibitors of Steroid Sulfatase".Journal of Medicinal Chemistry.43 (23):4465–4478.doi:10.1021/jm0001166.
  19. ^"Neue Spezialitäten".Klinische Wochenschrift.33 (31–32):773–774. 1955.doi:10.1007/BF01473523.ISSN 0023-2173.S2CID 1678069.
  20. ^Kahr H (8 March 2013).Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 20–.ISBN 978-3-7091-5694-0.
  21. ^Arends G, Zörnig H, Hager H, Frerichs G, Kern W (14 December 2013).Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1156–1157, 1164.ISBN 978-3-662-36329-4.
  22. ^Helwig B (1956).Moderne Arzneimittel: eine Spezialitätenkunde nach Indikationsgebieten für Ärzte und Apotheker. Wissenschaftliche Verlagsgesellschaft. p. 240.
Estrogens
ERTooltip Estrogen receptor agonists
Progonadotropins
Antiestrogens
ERTooltip Estrogen receptor antagonists
(incl.SERMsTooltip selective estrogen receptor modulators/SERDsTooltip selective estrogen receptor downregulators)
Aromatase inhibitors
Antigonadotropins
Others
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
Retrieved from "https://en.wikipedia.org/w/index.php?title=Methylestradiol&oldid=1336157051"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp